How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

29,491 results for

Intravenous Drug Abuse

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Drug-Drug Interactions in the Elderly

IV. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Drug-Drug Interactions in the Elderly." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Pharmacology About FPnotebook.com is a rapid access, point-of-care medical reference for primary care and emergency clinicians. Started in 1995, this collection now contains 6656 (...) Drug-Drug Interactions in the Elderly Drug-Drug Interactions in the Elderly Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Drug-Drug

2018 FP Notebook

142. Drug Interventions for Chronic Non-Cancer Pain

, Buchser E, Burton A, Caraway D, et al. Polyanalgesic Consensus Conference--2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain. Neuromodulation. 2012 Sep;15(5):467-82. PubMed: PM22849581 Drug Interventions for Chronic Non-Cancer Pain 2 8. Mailis A, Taenzer P. Evidence-based guideline for neuropathic pain interventional treatments: spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks. Pain Res Manag. 2012 (...) Syndrome 22. Azari P, Lindsay DR, Briones D, Clarke C, Buchheit T, Pyati S. Efficacy and safety of ketamine in patients with complex regional pain syndrome: a systematic review. CNS Drugs. 2012 Mar 1;26(3):215-28. PubMed: PM22136149 23. Dirckx M, Stronks DL, Groeneweg G, Huygen FJ. Effect of immunomodulating medications in complex regional pain syndrome: a systematic review. Clin J Pain. 2012 May;28(4):355-63. PubMed: PM22001668 Low Back Pain 24. Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

143. Biologic therapy for psoriasis

III or who have psoriasis that is persistent (i.e. that relapses rapidly off a therapy that cannot be continued long-term IV ) á British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 16 V www.medicines.org.uk/emc/ VI http://www.bad.org.uk/healthcare-professionals/forms-downloads Prescribing biologic therapy R6 Be aware of the benefits of, contraindications to and adverse effects associated with biologic therapies and reference the drug-specific SPCs V áá R7 (...) relate to other factors (for example, other co-therapies or the underlying disease) that the risk of fetal abnormalities in women with psoriasis who conceive on biologic therapy has not been adequately studied and therefore cannot be áá British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 20 X For example http://www.medicinesinpregnancy.org/Medicine--pregnancy XI There are no known interactions between biologic therapies and contraceptive methods (see drug-specific

2017 British Association of Dermatologists

144. Sotagliflozin tablets as an adjuct therapy to insulin for Type 1 diabetes mellitus

Breast Disease Haematology and Blood Products Health Promotion and Protection including Screening Immunology and Allergy Infectious Disease and Immunisation Mens Health and Sexual Health Mental Health Drug Abuse and Learning Difficulties Musculoskeletal Neurology and Neurosurgery Other Paediatrics and Neonatology Pregnancy and Childbirth Radiology Imaging and Nuclear Medicine Rehabilitation and Disability Renal Disease and Urology Respiratory Disease and Thoracic Surgery Skin Disease Burns and Wound (...) in development as these outputs are produced as required for our stakeholders. > > > Sotagliflozin tablets as an adjuct therapy to insulin for Type 1 diabetes mellitus Sotagliflozin tablets as an adjuct therapy to insulin for Type 1 diabetes mellitus September 2017 Sotagliflozin is a drug being developed to lower blood sugar levels in type 1 diabetes by increasing the amount of sugars excreted in the urine. It is taken once a day tablet in conjunction with insulin to prevent large rises and falls in blood

2017 NIHR Innovation Observatory

145. Arimoclomol for Niemann-Pick Disease type C - add-on therapy

Nutritional and Metabolic Eye Disease Gastrointestinal Pancreatic and Liver Disease Gynaecology Womens Sexual Health and Benign Breast Disease Haematology and Blood Products Health Promotion and Protection including Screening Immunology and Allergy Infectious Disease and Immunisation Mens Health and Sexual Health Mental Health Drug Abuse and Learning Difficulties Musculoskeletal Neurology and Neurosurgery Other Paediatrics and Neonatology Pregnancy and Childbirth Radiology Imaging and Nuclear Medicine (...) as required for our stakeholders. > > > Arimoclomol for Niemann-Pick Disease type C – add-on therapy Arimoclomol for Niemann-Pick Disease type C – add-on therapy July 2017 Arimoclomol is a medicine that is under investigation as a treatment for NPC. It is given by mouth as capsules. Arimoclomol helps the body’s cells to process accumulated lipids. If licensed, arimoclomol could offer an additional treatment option for people with NPC. Innovation Observatory Voice Leave a Reply Your email address

2017 NIHR Innovation Observatory

146. Rituximab (MabThera) maintenance therapy for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)

Immunology and Allergy Infectious Disease and Immunisation Mens Health and Sexual Health Mental Health Drug Abuse and Learning Difficulties Musculoskeletal Neurology and Neurosurgery Other Paediatrics and Neonatology Pregnancy and Childbirth Radiology Imaging and Nuclear Medicine Rehabilitation and Disability Renal Disease and Urology Respiratory Disease and Thoracic Surgery Skin Disease Burns and Wound Care Check All By clicking "subscribe" I confirm that I am happy to receive alerts. © 2019 NIHR (...) drugs, chemotherapy, radiation therapy or surgery. Load More Related Posts Time Central 4th Floor, Gallowgate Newcastle upon Tyne United Kingdom NE1 4BF Tel: +44 (0)191 2082259 Email: Join our mailing list? Name * First Last Email * I confirm that I am happy to receive newsletter updates * I confirm that I am happy to receive newsletter updates Email This field is for validation purposes and should be left unchanged. This iframe contains the logic required to handle AJAX powered Gravity Forms. Get

2017 NIHR Innovation Observatory

147. Abemaciclib in combination with fulvestrant for advanced or metastatic breast cancer after prior endocrine therapy

Sexual Health and Benign Breast Disease Haematology and Blood Products Health Promotion and Protection including Screening Immunology and Allergy Infectious Disease and Immunisation Mens Health and Sexual Health Mental Health Drug Abuse and Learning Difficulties Musculoskeletal Neurology and Neurosurgery Other Paediatrics and Neonatology Pregnancy and Childbirth Radiology Imaging and Nuclear Medicine Rehabilitation and Disability Renal Disease and Urology Respiratory Disease and Thoracic Surgery Skin (...) to currently approved daratumumab intravenous formulation. MM is a rare, incurable cancer of the plasma cells in the bone marrow where large amounts of abnormal plasma cells are produced and interfere with the production of platelets, red and white blood cells. People with MM will experience periods of time without symptoms followed by periods when the illness comes back (‘relapsed’ MM). Eventually the periods without symptoms will shorten and the illness will become immune to the drugs given to treat

2017 NIHR Innovation Observatory

148. Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value

of Medicine at Dartmouth No relevant conflicts of interest to disclose, defined as more than $10,000 in healthcare company stock or more than $5,000 in honoraria or consultancies during the previous year from health care manufacturers or insurers. ©Institute for Clinical and Economic Review, 2017 Page iv Evidence Report – Anabolic Therapies for Osteoporosis Table of Contents Executive Summary ES1 1. Background 1 1.1 Introduction 1 2. The Topic in Context 4 3. Summary of Coverage Policies and Clinical (...) and calcium intake, weight bearing exercise, and an oral medication from the bisphosphonate class of drugs. If patients are unable to tolerate oral bisphosphonates or compliance cannot be ascertained, then IV bisphosphonates are generally recommended. Bone is constantly broken down (resorption) and rebuilt; bisphosphonates work by decreasing bone resorption. There are several other drugs approved for osteoporosis that also decrease bone resorption (estrogen, calcitonin, raloxifene, denosumab

2017 California Technology Assessment Forum

149. Cognitive and Mind-Body Therapies for Chronic Low Back and Neck Pain: Effectiveness and Value

Cognitive and Mind-Body Therapies for Chronic Low Back and Neck Pain: Effectiveness and Value ©Institute for Clinical and Economic Review, 2017 Cognitive and Mind-Body Therapies for Chronic Low Back and Neck Pain: Effectiveness and Value Evidence Report October 4, 2017 Prepared for ©Institute for Clinical and Economic Review, 2017 Page i Chronic Low Back and Neck Pain – Evidence Report AUTHORS: Jeffrey A. Tice, MD Professor of Medicine University of California, San Francisco Varun Kumar, MBBS (...) , Perioperative and Pain Medicine Director, Stanford Comprehensive Interdisciplinary Pain Program Stanford University School of Medicine No relevant conflicts of interest to disclose, defined as more than $10,000 in healthcare company stock or more than $5,000 in honoraria or consultancies during the previous year from health care manufacturers or insurers. ©Institute for Clinical and Economic Review, 2017 Page iv Chronic Low Back and Neck Pain – Evidence Report Table of Contents Executive Summary ES1 1

2017 California Technology Assessment Forum

150. Management of Opioid Therapy (OT) for Chronic Pain

clinicians or specialists to study and consider the latest information on opioid therapy (OT) and how and whether to incorporate that information or recommendations into their practice. It can be used to provide specific information to guide a patient encounter, such as looking up the dosing of a medication used less frequently or the meaning of the urine drug testing (UDT) result. The section on tapering and its accompanying appendix can be used to assist in the development of a framework for guiding (...) , Washington, DC & Office of Evidence Based Practice, U.S. Army Medical Command Version 3.0 – 2017 Based on evidence reviewed through December 2016V A / D o D Cli ni cal P r a cti ce G ui d el i n e f o r O p ioid T h e r a p y for Ch r on ic Pa in February 2017 Page 3 of 198 Table of Contents I. Introduction 5 II. How to Use This Clinical Practice Guideline 6 7 10 11 12 13 14 15 15 16 16 19 20 21 21 26 26 27 27 31 III. Recommendations IV. Algorithm A. Module A: Determination of Appropriateness for Opioid

2017 VA/DoD Clinical Practice Guidelines

151. Olaparib (Lynparza) tablets for recurrent platinum-sensitive BRCA-mutated ovarian cancer – maintenance therapy

. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Olaparib (Lynparza) tablets for recurrent platinum-sensitive BRCA-mutated ovarian cancer – maintenance therapy Olaparib (Lynparza) tablets for recurrent platinum-sensitive BRCA-mutated ovarian cancer – maintenance therapy June 2017 Olaparib is a drug that kills cancer cells, and is already recommended by NICE as an option for patients with this type of ovarian cancer (...) too many white blood cells are produced. As these cells develop abnormally, they are unable to function and fight infection and stop the production of healthy blood cells. The disease is chronic and develops slowly. R/R CLL means the cancer has come back after treatment and reaching remission, or the cancer has failed to respond to treatment. Treatment options for R/R CLL include targeted therapy drugs, chemotherapy, radiation therapy or surgery. Load More Related Posts Time Central 4th Floor

2017 NIHR Innovation Observatory

152. Nabilone for Non-chemotherapy-Associated Nausea and Weight Loss Due to Medical Conditions

daily to manage intractable nausea and vomiting after failure of other alternatives such as scopolamine, prochlorperazine, dimenhydrinate, and metoclopramide, or inability to tolerate these drugs. 10,11 Both patients were near end of life at the time of treatment. 2. What is the clinical effectiveness and safety of nabilone for use in the treatment of weight loss due to medical conditions? One retrospective cohort study evaluated the effectiveness of the oral cannabinoids (OCs) nabilone (...) advanced liver biopsy stages, had a history of drug or alcohol abuse and were more likely to have a co-infection with HCV. These baseline differences and other possible confounding variables were not accounted for in the statistical analysis and confidence intervals were not reported. A database was used to retrospectively capture OC use over a 3.5 year period. It is possible that some individuals may have had exposure to OCs from other sources not captured in the database, making misclassification

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

153. Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

/treatment Phase Anatomic Stage IV Breast Cancer AJCC v8 Estrogen Receptor Positive HER2/Neu Negative Metastatic Breast Carcinoma Metastatic Malignant Neoplasm in the Bone Progesterone Receptor Positive Prognostic Stage IV Breast Cancer AJCC v8 Drug: Anastrozole Drug: Exemestane Drug: Fulvestrant Drug: Letrozole Drug: Palbociclib Radiation: Radiation Therapy Drug: Tamoxifen Phase 2 Detailed Description: PRIMARY OBJECTIVE: I. To evaluate the response rate three months post-conventionally fractionated (...) of Bone Metastasis in Breast Cancer Patients Actual Study Start Date : February 8, 2019 Estimated Primary Completion Date : March 31, 2020 Estimated Study Completion Date : March 31, 2020 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Radiation, palbociclib, hormone therapy Patients undergo radiation therapy over 5-10 days and receive palbociclib PO QD on days 1-21

2018 Clinical Trials

154. A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

) during the treatment period. Masking: Double (Participant, Investigator) Masking Description: This is a phase 4 double blind study, which will use a triple dummy design for dosing. Primary Purpose: Treatment Official Title: A Phase IV, 12-week, Randomised, Double-blind, Triple Dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) With Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) Based on Lung Function and Symptoms (...) -acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study. Drug: FF/UMEC/VI Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning Drug: Placebo to match budesonide/formoterol Subjects will be administered two inhalations of matching placebo twice daily via MDI Drug: tiotropium Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device Drug: placebo to match tiotropium Subjects will receive

2018 Clinical Trials

155. A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

) during the treatment period. Masking: Double (Participant, Investigator) Masking Description: This is a phase 4 double blind study, which will use a triple dummy design for dosing. Primary Purpose: Treatment Official Title: A Phase IV, 12-week, Randomised, Double-blind, Triple Dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) With Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) Based on Lung Function and Symptoms (...) -acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study. Drug: FF/UMEC/VI Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning Drug: Placebo to match budesonide/formoterol Subjects will be administered two inhalations of matching placebo twice daily via MDI Drug: tiotropium Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device Drug: placebo to match tiotropium Subjects will receive

2018 Clinical Trials

156. Systemic Therapy With or Without Local Consolidative Therapy in Treating Participants With Oligometastatic Solid Tumor

.) no LCT among randomized patients. SECONDARY OBJECTIVES: I. In patients with oligometastatic malignancies, to assess overall survival (OS) with upfront LCT vs. no LCT among randomized patients. II. In patients with oligometastatic malignancies, to assess time to next line systemic therapy with upfront LCT vs. no LCT. III. In patients with oligometastatic malignancies, to assess time to new lesion failure with upfront LCT vs. no LCT. IV. To assess safety/tolerability of upfront LCT in patients (...) : Participants receive up-front standard of care LCT including but not limited to surgical resection, cryotherapy, and radiofrequency ablation. Participants then receive routine drug therapy. ARM II: Participants receive routine drug therapy. Participants may later receive LCT at the discretion of doctor. After completion of study, participants are followed up every 18 weeks for 1 year Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment

2018 Clinical Trials

157. Efficacy of Complementary and Alternative Medicine Therapies for Posttraumatic Stress Disorder

, accessible, adequate, or congruent with patient preferences. Complementary and Alternative Medicine CAM is commonly used to describe a wide range of therapies that are not generally considered standard components of modern medicine as practiced by physicians in the U.S. Yet, many CAM treatments, such as acupuncture, are part of traditional medical practices in other parts 8 Efficacy of Complementary and Alternative Medicine Therapies for Posttraumatic Stress Disorder Evidence-based Synthesis Program (...) of the world. The National Center for Complementary and Alternative Medicine (NCCAM) in the National Institutes of Health (NIH) has proposed a classification system for CAM therapies that includes natural products (e.g., dietary supplements, herbal remedies, probiotics), mind- body medicine (e.g., meditation, yoga, acupuncture), manipulative and body-based practices (e.g., spinal manipulation, massage therapy), whole medical systems (e.g., traditional Chinese medicine, Ayurvedic medicine), and other

2011 Veterans Affairs Evidence-based Synthesis Program Reports

158. Abusive Head Trauma and the Eye in Infancy

please contact events@rcophth.ac.uk 2 Executive Summary A child suspected of abusive head injury is referred by paediatricians to an ophthalmologist for evaluation. The incidence of abusive head injury in children is highest in infancy and less frequently seen in children over 3 years of age. Retinal haemorrhages have a high positive predictive rate for abusive head injury. In the presence of head injury without any plausible medical explanation the description of the retinal findings help (...) chapters, whereby each topic will be followed by the related bibliography to facilitate finding references related to a particular topic. i. Aetiological factors and experimental models ii. Clinical features and pathology iii. Differential diagnosis and confounding conditions iv. Guidance for the ophthalmologist. References (1) The Ophthalmology Child Abuse Working Party. Child abuse and the eye. Eye 1999;13(1):3-10. (2) Adams G, Ainsworth J, Butler L, Bonshek R, Clarke M, Doran R, et al. Update from

2013 Royal College of Ophthalmologists

159. The Severity of Dependence Scale detects medication misuse and dependence among hospitalized older patients. Full Text available with Trip Pro

and DSM-IV criteria for substance abuse and dependence (Pearson's correlation coefficient = 0.61, p < 0.001). The uni-dimensionality of the SDS was documented.The SDS is reliable, valid and capable of detecting medication misuse and dependence among hospitalized older patients, with good diagnostic performance. The scale thus holds promise for use in both clinical and research contexts.ClinicalTrials.gov Identifier: NCT03162081 . Registered 3 May 2017. (...) DSM-IV criteria for substance abuse and dependence as the reference standard. We also performed an exploratory factor analysis and assessment of internal consistency using Cronbach's alpha.The area under the ROC curve was 0.86 (95%CI = 0.79-0.93; p < 0.001). A score of 5.5 was determined as the optimal cutoff for detecting CNSD misuse and dependence among older patients. Cronbach's alpha obtained was satisfactory (α = 0.73). There was a significant positive correlation between the SDS score

2019 BMC Geriatrics

160. Evaluation of an emergency department buprenorphine induction and medication-assisted treatment referral program. (Abstract)

and interquartile ranges for continuous variables, and frequencies as percentages for categorical data.Overall, 219 patients were seen and induced with buprenorphine in the emergency department. Mean age was 35 years old (SD 10.3) and 56% were male. Intravenous opioids were most commonly abused at 75%. Our primary outcome of interest was the percentage of patients enrolled in MAT at 30 days, which occurred in 49.3% of our population. Patients were in moderate withdrawal based on initial COWS scores of 13.1(SD (...) Evaluation of an emergency department buprenorphine induction and medication-assisted treatment referral program. Emergency departments are struggling to manage the increasing number of patients seen for opioid use disorders and opioid overdose. With opioid overdose deaths rising at alarming rates, emergency physicians are beginning to induce patients with long-acting opioids such as buprenorphine and referring patients to outpatient medication-assisted treatment facilities. The objective

2019 American Journal of Emergency Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>